Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
1992 3
1993 1
1994 3
1995 3
1996 1
1997 4
1998 3
1999 3
2000 4
2001 6
2002 7
2003 10
2004 7
2005 16
2006 13
2007 8
2008 4
2009 9
2010 7
2011 8
2012 6
2013 6
2014 4
2015 4
2016 8
2017 3
2019 3
2020 1
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

154 results
Results by year
Filters applied: . Clear all
Page 1
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P = 0.00001). ...
The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61 …
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, Hawley CM, Khalidi N, Floßmann O, Wald R, Girard LP, Levin A, Gregorini G, Harper L, Clark WF, Pagnoux C, Specks U, Smyth L, Tesar V, Ito-Ihara T, de Zoysa JR, Szczeklik W, Flores-Suárez LF, Carette S, Guillevin L, Pusey CD, Casian AL, Brezina B, Mazzetti A, McAlear CA, Broadhurst E, Reidlinger D, Mehta S, Ives N, Jayne DRW; PEXIVAS Investigators. Walsh M, et al. N Engl J Med. 2020 Feb 13;382(7):622-631. doi: 10.1056/NEJMoa1803537. N Engl J Med. 2020. PMID: 32053298 Free PMC article. Clinical Trial.
Glucose targets for preventing diabetic kidney disease and its progression.
Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, Craig JC, Strippoli GF. Ruospo M, et al. Cochrane Database Syst Rev. 2017 Jun 8;6(6):CD010137. doi: 10.1002/14651858.CD010137.pub2. Cochrane Database Syst Rev. 2017. PMID: 28594069 Free PMC article. Review.
[Chronic kidney disease].
Anders HJ. Anders HJ. Med Klin (Munich). 2005 Nov 15;100(11):714-21. doi: 10.1007/s00063-005-1089-y. Med Klin (Munich). 2005. PMID: 16328179 Review. German.
The management of the renal patient includes attempts to make an early diagnosis, prevention of disease progression, and treatment of common complications of chronic kidney disease. ...
The management of the renal patient includes attempts to make an early diagnosis, prevention of disease progression, and treatment of …
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Wright JT Jr, et al. JAMA. 2002 Nov 20;288(19):2421-31. doi: 10.1001/jama.288.19.2421. JAMA. 2002. PMID: 12435255 Clinical Trial.
154 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page